STAT August 22, 2018
Rebecca Robbins

Clad in T-shirts, the startup founders cycled through the stage, each whizzing through a two-minute pitch packed with wildly optimistic promises and generously large market estimates.

Some pitched the usual Silicon Valley fare, like drones and live-streamed fitness classes and laundry detergent subscriptions aimed at hip millennials. But more than ever before, many of them pitched ideas for the life sciences: Transistors for synthetic biology. An experimental cell therapy for patients with liver disease. And a diagnostic that aims to bypass needles altogether by collecting blood from women’s used menstrual pads — and in doing so collect reams of data that are invaluable to pharma companies.

The occasion was Demo Day, something of a biannual ritual here at the end...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Investments, Precision Medicine, Technology, Trends
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article